Results 271 to 280 of about 29,806 (309)

[Direct-acting antiviral-resistant variant].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting ...
Michio, Imamura, Kazuaki, Chayama
openaire   +1 more source

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Surgical Oncology Clinics of North America
Therapy for chronic hepatitis C virus infection with direct-acting antiviral agents (DAAs) has been highly successful in achieving sustained virological response (SVR) with associated improvements in liver dysfunction, liver-related mortality, and transplant-free survival.
Ifrah, Fatima, Neehar D, Parikh, Alisa, Likhitsup   +2 more
openaire   +2 more sources

Interferon free therapy with direct acting antivirals for HCV

Liver International, 2013
AbstractThe current treatment for hepatitis C virus (HCV) genotype 1 chronic infection is the addition of direct‐acting antivirals (DAA) with a protease inhibitor (telaprevir or boceprevir) to the pegylated interferon (PEG‐IFN) plus ribavirin (RBV) regimen.
Tarik, Asselah, Patrick, Marcellin
openaire   +2 more sources

Direct-acting antiviral treatment for patients with hepatocellular carcinoma

Current Opinion in Gastroenterology, 2018
Hepatocellular carcinoma (HCC) affects a significant portion of patients with hepatitis C. The use of direct-acting antiviral (DAA) agents has transformed the disease outcomes in this patient group.Hepatitis C virus (HCV) response to DAAs can be affected by the presence of HCC, whereas DAA therapy may affect the risk of HCC recurrence in patients with ...
Tatyana, Kushner, Douglas, Dieterich, Behnam, Saberi   +2 more
openaire   +2 more sources

Direct-Acting Antiviral Agents

Clinics in Liver Disease, 2015
Tatyana Kushner, Vandana Khungar
openaire   +1 more source

Direct-acting antiviral treatment for HCV

The Lancet Infectious Diseases, 2016
Stelliana, Goutzamanis, Joseph, Doyle, Alexander, Thompson, Margaret, Hellard, Peter, Higgs   +4 more
openaire   +2 more sources

Direct-acting antiviral (DAA) actions in treatment-naïve patients

Clinics and Research in Hepatology and Gastroenterology, 2011
The introduction of telaprevir (TVR) and boceprevir (BOC), the first approved protease inhibitors against hepatitis C virus (HCV), into clinical practice represented the start of an exciting new era of HCV treatment. In addition to improving sustained virological response (SVR) rates in HCV genotype-1 treatment-naïve patients, these drugs administered ...
openaire   +2 more sources

Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals

Expert Opinion on Pharmacotherapy
With the introduction of highly effective and safe therapies with next-generation direct-acting antivirals (DAAs), that act without interferon, hepatitis C virus (HCV) infection remains the only treatable chronic infectious disease.The review aims to provide an overview of the therapy revolution with a description of specific DAAs, their mechanisms of ...
Krystyna, Dobrowolska, Michał, Brzdęk, Piotr, Rzymski, Robert, Flisiak, Małgorzata, Pawłowska, Jakub, Janczura, Kinga, Brzdęk, Dorota, Zarębska-Michaluk   +7 more
openaire   +2 more sources

Direct acting antiviral‐induced/exacerbated psoriasis: Addendum!

Dermatologic Therapy, 2019
Ayman Abdelmaksoud, Michelangelo Vestita
openaire   +2 more sources

Direct-acting antiviral treatment for hepatitis C

The Lancet, 2019
Jacinta A, Holmes, Stephanie M, Rutledge, Raymond T, Chung   +2 more
openaire   +2 more sources